Drug intelligence / Profile preview

nystatin + paromomycin + vancomycin

Development stage: Unknown
Lead developer: Streptomyces
Modality: Small Molecules
Administration: Oral

Overview

A combination of three antimicrobial agents used for intestinal decontamination. Nystatin is an antifungal agent that targets fungal infections, paromomycin is an aminoglycoside antibiotic used to treat intestinal amebiasis and reduce ammonia-producing bacteria in hepatic coma, and vancomycin is a glycopeptide antibiotic that targets gram-positive bacteria, particularly in the intestines. This combination is typically administered orally as a nonabsorbable antibiotic regimen to prevent infections in immunocompromised patients or those with liver disease.

Targets

ErgosterolD-Ala-D-Ala (D-Ala-D-Ala terminus)30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on nystatin + paromomycin + vancomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nystatin + paromomycin + vancomycin.

Explore the full profile